Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna
In this edition:
Bevacizumab and Survival in Metastatic Breast Cancer
Source: N Engl J Med 357:26
George Canellos, Dana-Farber Cancer Institute, Boston
Progresson-free survival, but not overall survival, was extended in patients with metastatic breast cancer who were randomly assigned to receive paclitaxel with bevacizumab as compared with paclitaxel alone.
Risks From Stopping Cancer Trials Early
Source: Annals of Oncology, April 9th, 2008
Giovanni Apolone, Mario Negri Institute, Milan
Stuart Pocock, London School of Hygiene and Tropical Medicine
New research highlights the dangers of stopping cancer clinical trials early following interim analysis before originally planned sample sizes have been reached, especially when surrogate end points are used.